Desipramine treatment in panic disorder

Oren Kalus, Gregory M. Asnis, Eileen Rubinson, Rene Kahn, Jill M. Harkavy Friedman, Naveed Iqbal, Dan Grosz, Herman van Praag, Wiepke Cahn

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Apart from imipramine (IMI), the efficacy of tricyclic antidepressants in panic disorder (PD) has received surprisingly little investigation. The authors report on a 6 week open trial of desipramine (DMI) preceded by a 10 day placebo lead-in, in 15 patients with PD. By week 6, 80% of the patients were globally rated as much or very much improved on a mean dose of 198 mg. Much of the improvement resulted from a reduction in non-panic attack symptomatology (i.e., psychic, somatic and phobic anxiety). longer duration of illness, male gender and residual psychic anxiety were associated with poorer response in a subgroup of patients. DMI caused minimal intolerable side effects, suggesting possible compliance advantages in comparison to IMI. Beyond supporting the efficacy of DMI in PD, the results of the study point to a significant medication responsive non-panic illness component and caution against over-relying on panic attacks in assessing both illness severity and treatment response.

Original languageEnglish
Pages (from-to)239-244
Number of pages6
JournalJournal of Affective Disorders
Volume21
Issue number4
DOIs
StatePublished - Apr 1991
Externally publishedYes

Keywords

  • Desipramine
  • Panic disorder

Fingerprint

Dive into the research topics of 'Desipramine treatment in panic disorder'. Together they form a unique fingerprint.

Cite this